Overview
- Lilly agreed to pay $55 million in upfront and near-term milestones, with up to $1.3 billion in additional development and commercial milestones plus royalties if any drug is approved.
- Nimbus will use its artificial intelligence platform to identify oral candidates while Lilly contributes metabolic-disease expertise to advance an easy-to-take obesity medicine.
- The announcement comes as Novo Nordisk begins U.S. sales of FDA-approved Wegovy tablets, highlighting growing momentum for oral weight-loss options.
- Nimbus previously sold an AI-designed psoriasis compound to Takeda in a deal worth up to $6 billion, and that drug recently cleared two late-stage trials ahead of planned regulatory filings.
- The collaboration extends a 2022 Lilly–Nimbus research pact on oral cardiometabolic therapies and reflects wider industry adoption of AI aligned with the FDA’s push to reduce animal testing.